INTERESTED IN THIS RESEARCH?
Contact our analysts for inquiries, samples, and expert insights.
REPORT OUTLOOK
| Market Size | CAGR | Dominating Region |
|---|---|---|
| 10.90 billion by 2029 | 6.9% | North America |
| by Type | by Treatment Type | by Molecule Type | by Region |
|---|---|---|---|
|
|
|
|
SCOPE OF THE REPORT
Lung Cancer Therapeutics Market Overview
The global lung cancer therapeutics market was valued at 6.83 billion in 2022 and is projected to reach 10.90 billion by 2029, growing at a CAGR of 6.9% from 2022 to 2029.
Cancer is a condition in which the body’s cells proliferate unchecked. The most common type of cancer in the world, lung cancer affects the tissues of the lungs. Having lung cancer makes it more difficult for the blood to receive oxygen. The majority of lung cancers are non-small cell lung cancers, which have the highest mortality rate in both the male and female populations. Lung cancer is the name for cancer that first appears in the lungs. In addition to lymph nodes and other body organs including the brain, lung cancer can also start in the lungs. Lung cancer can potentially spread from other organs. Small cell and non-small cell lung cancers—including adenocarcinoma and squamous cell carcinoma—are typically categorized into two basic categories. They develop differently and respond to treatment in different ways. The prevalence of non-small cell lung cancer exceeds that of small cell lung cancer.
Lung cancer is defined as the unchecked growth of abnormal cells in one or both lungs, most frequently in air-passing cells. Normal lung tissue does not form from the aberrant cells. Tumors develop from their rapid cell proliferation. Cancer is a condition that causes the body’s cells to proliferate uncontrollably. In addition to lymph nodes and other organs including the brain, lung cancer can also start in the lungs. There is a potential that cancer that has progressed to other organs will also spread to the lungs. The lungs’ capacity to deliver oxygen to the bloodstream is compromised by lung cancer.
Lung cancer has the greatest fatality rate of any malignancy in both men and women, making it one of the most frequently diagnosed diseases. Initial lung carcinomas that start in epithelial cells include small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC), and lung carcinoid tumor. Under a microscope, the size of these tumor cells can be observed and identified. Adenocarcinoma, large-cell carcinoma, and squamous-cell carcinoma are the three types of NSCLC. A form of tumor that combines both mixed and small cell carcinoma is known as small cell lung cancer (SCLC), sometimes known as oat cell cancer.
| ATTRIBUTE | DETAILS |
| Study period | 2022-2029 |
| Base year | 2021 |
| Estimated year | 2022 |
| Forecasted year | 2022-2029 |
| Historical period | 2018-2020 |
| Unit | Value (USD Billion) |
| Segmentation | By Cancer Type, Molecule Type, Treatment Type, and Region. |
| By Cancer Type
 |
|
| By Molecule Type
 |
|
| By Treatment Type
 |
|
| By Region
 |
|
Lung Cancer Therapeutics Market Segment Analysis:
Based on cancer type, molecule type, treatment type, and region, the global market for lung cancer therapeutics is divided into these categories.
Small cell lung cancer and non-small cell lung cancer are the two subtypes of lung cancer therapies, respectively. Any form of lung cancer with an epithelial component that is not small-cell lung cancer (SCLC) is referred to as non-small-cell lung carcinoma. Of all lung malignancies, NSCLC makes up roughly 85%. In contrast to small-cell carcinoma, NSCLCs are generally less susceptible to treatment. Although chemotherapy is increasingly utilized both preoperatively (neoadjuvant chemotherapy) and postoperatively (adjuvant chemotherapy), the primary method of treatment for them is, where it is possible, surgical resection with the goal of curing the condition.
Small-cell lung cancer is a disorder in which lung tissues give rise to malignant (cancer) cells. It first concentrates on the bronchi, or breathing passages, in the center of the chest. Smoking is the main factor in small-cell lung cancer development. The more lethal of the two kinds of lung cancer is SCLS. Patients with SCLC have a 5-year survival rate of 7%. Cancer cells are quite small, but they multiply quickly and grow into huge tumors. Small-cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma (solid tumor), accounting for roughly 10-15% of all instances of lung cancer, according to an article published in NCBI. Chemotherapy and radiation are routinely used to treat SCLC.
The lung cancer therapies market uses two types of chemicals: small molecules and biologics. A small molecule or macromolecule is a low molecular weight organic chemical that may control a biological process and has a size of about 1 nm in the fields of molecular biology and pharmacology. Small molecules make up many medications; the words are interchangeable in the literature. Although their component monomers are frequently regarded as small molecules, larger structures like nucleic acids, proteins, and many polysaccharides are not small molecules. While The term “biologicals” refers to a broad category of medications that includes vaccines, growth factors, immune modulators, monoclonal antibodies, and items made from human blood and plasma.
Lung cancer therapeutics have the following treatment types Chemotherapy, Radiation Therapy, Targeted Therapy, and Immunotherapy. Since targeted therapy is significantly more effective than chemotherapy, it is becoming more and more well-liked as a cancer treatment choice. Targeted therapy has an 80% success rate compared to chemotherapy’s 30% success rate. High doses of radiation are used in radiation therapy, a cancer treatment, to destroy cancer cells and reduce tumor size. As with X-rays of your teeth or broken bones, radiation is utilized at low doses in X-rays to see inside your body. A type of treatment that targets particular chemicals needed by cancer cells for survival and spread using medications or other substances. The method that targeted therapies cure cancer varies. One sort of cancer treatment is immunotherapy. It makes use of chemicals produced by the body or in a lab to strengthen the immune system and assist the body in locating and eliminating cancer cells. Numerous forms of cancer can be treated using immunotherapy. It may be used alone or in conjunction with other cancer treatments such as chemotherapy.
Lung Cancer Therapeutics Market Players:
The major players operating in the global lung cancer therapeutics industry include the major market players are GlaxoSmithKline plc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, AstraZeneca, Merck & Co., Inc., Sanofi, Johnson & Johnson Services, Inc., ALLERGAN, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company and others.
Recent News:
19 December 2022: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology.
8 June 2022: Sanofi launched its first Digital Accelerator fueled by new talent and focused on growth.
Lung Cancer Therapeutics Market Regional Analysis:
Geographically, the lung cancer therapeutics market is segmented into North America, South America, Europe, APAC, and MEA.
- North America: includes the US, Canada, Mexico
- Europe: includes the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe
- Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN, and the Rest of APAC
- South America: includes Brazil, Argentina, and the Rest of South America
- Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and the Rest of MEA
North America had the largest market for lung cancer treatments in 2021, and it is projected that this status will remain during the projection period. The rising incidence of lung cancer and the expanding usage of better diagnosis and lung cancer medications for treatment have led to an increase in the demand for lung cancer treatments in this region. The existence of several top biopharmaceutical companies in this region has considerably supported the growth and expansion of the lung cancer therapeutics market. In North America, health insurance is more widely available, which has increased access to pricey, cutting-edge therapies. The region’s improved access to state-of-the-art healthcare facilities and its strong and well-established healthcare infrastructure have both significantly contributed to the market’s growth. In terms of pharmaceutical sector spending on R&D, North America is at the top of the world rankings. A huge 36% of the market was controlled by the region in 2022.
Key Market Segments: Lung Cancer Therapeutics Market
Lung Cancer Therapeutics Market by Cancer Type, 2020-2029, (USD Billion)
- Non-small cell lung cancer
- Small cell lung cancer
Lung Cancer Therapeutics Market by Molecule Type, 2022-2029, (USD Billion)
- Small molecules
- Biologics
Lung Cancer Therapeutics Market by Treatment Type, 2022-2029, (USD Billion)Â
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
- Immunotherapy
Lung Cancer Therapeutics Market by Region, 2022-2029, (USD Billion)Â
- North America
- Europe
- Asia Pacific
- South America
- Middle East and Africa
Important Countries in All Regions Are Covered
Who Should Buy? Or Key stakeholders
- Manufacturing
- End-Use Industries
- BFSI
- Automotive
- Manufacturing & Construction
- Regulatory Authorities
- Research Organizations
- Information Technology
- Materials & Chemicals
Key Question Answered
- What is the expected growth rate of the lung cancer therapeutics market over the next 7 years?
- Who are the major players in the lung cancer therapeutics market and what is their market share?
- What are the end-user industries driving demand for the market and what is their outlook?
- What are the opportunities for growth in emerging markets such as Asia-Pacific, the Middle East, and Africa?
- How is the economic environment affecting the lung cancer therapeutics market, including factors such as interest rates, inflation, and exchange rates?
- What is the expected impact of government policies and regulations on the lung cancer therapeutics market?
- What is the current and forecasted size and growth rate of the global lung cancer therapeutics market?
- What are the key drivers of growth in the lung cancer therapeutics market?
- Who are the major players in the market and what is their market share?
- What are the distribution channels and supply chain dynamics in the lung cancer therapeutics market?
- What are the technological advancements and innovations in the lung cancer therapeutics market and their impact on product development and growth?
- What are the regulatory considerations and their impact on the market?
- What are the challenges faced by players in the lung cancer therapeutics market and how are they addressing these challenges?
- What are the opportunities for growth and expansion in the lung cancer therapeutics market?
- What are the services offerings and specifications of leading players in the market?
Exactitude Consultancy Services Key Objectives:
- Increasing sales and market share
- Developing new technology
- Improving profitability
- Entering new markets
- Enhancing brand reputation
Table of Content
- INTRODUCTION
- MARKET DEFINITION
- MARKET SEGMENTATION
- RESEARCH TIMELINES
- ASSUMPTIONS AND LIMITATIONS
- RESEARCH METHODOLOGY
- DATA MINING
- SECONDARY RESEARCH
- PRIMARY RESEARCH
- SUBJECT-MATTER EXPERTS’ ADVICE
- QUALITY CHECKS
- FINAL REVIEW
- DATA TRIANGULATION
- BOTTOM-UP APPROACH
- TOP-DOWN APPROACH
- RESEARCH FLOW
- DATA SOURCES
- DATA MINING
- EXECUTIVE SUMMARY
- MARKET OVERVIEW
- GLOBAL LUNG CANCER THERAPEUTICS MARKET OUTLOOK
- MARKET DRIVERS
- MARKET RESTRAINTS
- MARKET OPPORTUNITIES
- IMPACT OF COVID-19 ON THE LUNG CANCER THERAPEUTICS MARKET
- PORTER’S FIVE FORCES MODEL
- THREAT FROM NEW ENTRANTS
- THREAT FROM SUBSTITUTES
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF CUSTOMERS
- DEGREE OF COMPETITION
- INDUSTRY VALUE CHAIN ANALYSIS
- GLOBAL LUNG CANCER THERAPEUTICS MARKET OUTLOOK
- GLOBAL LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE, 2020-2029, (USD BILLION)
- NON-SMALL CELL LUNG CANCER
- SMALL CELL LUNG CANCER
- GLOBAL LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE, 2020-2029, (USD BILLION)
- SMALL MOLECULES
- BIOLOGICS
- GLOBAL LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE, 2020-2029, (USD BILLION)
- CHEMOTHERAPY
- RADIATION THERAPY
- TARGETED THERAPY
- IMMUNOTHERAPY
- GLOBAL LUNG CANCER THERAPEUTICS MARKET BY REGION, 2020-2029, (USD BILLION)
- NORTH AMERICA
- US
- CANADA
- MEXICO
- SOUTH AMERICA
- BRAZIL
- ARGENTINA
- COLOMBIA
- REST OF SOUTH AMERICA
- EUROPE
- GERMANY
- UK
- FRANCE
- ITALY
- SPAIN
- RUSSIA
- REST OF EUROPE
- ASIA PACIFIC
- INDIA
- CHINA
- JAPAN
- SOUTH KOREA
- AUSTRALIA
- SOUTH-EAST ASIA
- REST OF ASIA PACIFIC
- MIDDLE EAST AND AFRICA
- UAE
- SAUDI ARABIA
- SOUTH AFRICA
- REST OF MIDDLE EAST AND AFRICA
- NORTH AMERICA
- COMPANY PROFILES*(BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCTS OFFERED, RECENT DEVELOPMENTS)
- GLAXOSMITHKLINE PLC.
- PFIZER INC.
- SUN PHARMACEUTICAL INDUSTRIES LTD.
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
- NOVARTIS AG
- ASTRAZENECA
- MERCK & CO., INC.
- SANOFI
- JOHNSON & JOHNSON SERVICES, INC.
- ALLERGAN
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- BRISTOL-MYERS SQUIBB COMPANYÂ *THE COMPANY LIST IS INDICATIVE
  LIST OF TABLES
TABLE 1Â Â Â Â Â Â Â Â Â GLOBAL LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 2Â Â Â Â Â Â Â Â Â GLOBAL LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 3Â Â Â Â Â Â Â Â Â GLOBAL LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 4Â Â Â Â Â Â Â Â Â GLOBAL LUNG CANCER THERAPEUTICS MARKET BY REGION (USD BILLION) 2020-2029
TABLE 5Â Â Â Â Â Â Â Â Â NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 6Â Â Â Â Â Â Â Â Â NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 7Â Â Â Â Â Â Â Â Â NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 8Â Â Â Â Â Â Â Â Â NORTH AMERICA LUNG CANCER THERAPEUTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 9Â Â Â Â Â Â Â Â Â US LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 10Â Â Â Â Â Â US LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 11Â Â Â Â Â Â US LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 12Â Â Â Â Â Â CANADA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 13Â Â Â Â Â Â CANADA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 14Â Â Â Â Â Â CANADA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 15Â Â Â Â Â Â MEXICO LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 16Â Â Â Â Â Â MEXICO LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 17Â Â Â Â Â Â MEXICO LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 18Â Â Â Â Â Â SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 19Â Â Â Â Â Â SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 20Â Â Â Â Â Â SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 21Â Â Â Â Â Â SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 22Â Â Â Â Â Â BRAZIL LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 23Â Â Â Â Â Â BRAZIL LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 24Â Â Â Â Â Â BRAZIL LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 25Â Â Â Â Â Â ARGENTINA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 26Â Â Â Â Â Â ARGENTINA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 27Â Â Â Â Â Â ARGENTINA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 28Â Â Â Â Â Â COLOMBIA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 29Â Â Â Â Â Â COLOMBIA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 30Â Â Â Â Â Â COLOMBIA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 31Â Â Â Â Â Â REST OF SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 32Â Â Â Â Â Â REST OF SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 33Â Â Â Â Â Â REST OF SOUTH AMERICA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 34Â Â Â Â Â Â ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 35Â Â Â Â Â Â ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 36Â Â Â Â Â Â ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 37Â Â Â Â Â Â ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 38Â Â Â Â Â Â INDIA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 39Â Â Â Â Â Â INDIA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 40Â Â Â Â Â Â INDIA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 41Â Â Â Â Â Â CHINA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 42Â Â Â Â Â Â CHINA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 43Â Â Â Â Â Â CHINA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 44Â Â Â Â Â Â JAPAN LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 45Â Â Â Â Â Â JAPAN LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 46Â Â Â Â Â Â JAPAN LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 47Â Â Â Â Â Â SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 48Â Â Â Â Â Â SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 49Â Â Â Â Â Â SOUTH KOREA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 50Â Â Â Â Â Â AUSTRALIA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 51Â Â Â Â Â Â AUSTRALIA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 52Â Â Â Â Â Â AUSTRALIA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 53Â Â Â Â Â Â SOUTH-EAST ASIA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 54Â Â Â Â Â Â SOUTH-EAST ASIA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 55Â Â Â Â Â Â SOUTH-EAST ASIA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 56Â Â Â Â Â Â REST OF ASIA PACIFIC LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 57Â Â Â Â Â Â REST OF ASIA PACIFIC LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 58Â Â Â Â Â Â REST OF ASIA PACIFIC LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 59Â Â Â Â Â Â EUROPE LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 60Â Â Â Â Â Â EUROPE LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 61Â Â Â Â Â Â EUROPE LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 62Â Â Â Â Â Â EUROPE LUNG CANCER THERAPEUTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 63Â Â Â Â Â Â GERMANY LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 64Â Â Â Â Â Â GERMANY LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 65Â Â Â Â Â Â GERMANY LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 66Â Â Â Â Â Â UK LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 67Â Â Â Â Â Â UK LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 68Â Â Â Â Â Â UK LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 69Â Â Â Â Â Â FRANCE LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 70Â Â Â Â Â Â FRANCE LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 71Â Â Â Â Â Â FRANCE LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 72Â Â Â Â Â Â ITALY LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 73Â Â Â Â Â Â ITALY LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 74Â Â Â Â Â Â ITALY LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 75Â Â Â Â Â Â SPAIN LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 76Â Â Â Â Â Â SPAIN LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 77Â Â Â Â Â Â SPAIN LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 78Â Â Â Â Â Â RUSSIA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 79Â Â Â Â Â Â RUSSIA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 80Â Â Â Â Â Â RUSSIA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 81Â Â Â Â Â Â REST OF EUROPE LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 82Â Â Â Â Â Â REST OF EUROPE LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 83Â Â Â Â Â Â REST OF EUROPE LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 84Â Â Â Â Â Â MIDDLE EAST AND AFRICA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 85Â Â Â Â Â Â MIDDLE EAST AND AFRICA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 86Â Â Â Â Â Â MIDDLE EAST AND AFRICA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 87Â Â Â Â Â Â MIDDLE EAST AND AFRICA LUNG CANCER THERAPEUTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 88Â Â Â Â Â Â UAE LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 89Â Â Â Â Â Â UAE LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 90Â Â Â Â Â Â UAE LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 91Â Â Â Â Â Â SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 92Â Â Â Â Â Â SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 93Â Â Â Â Â Â SAUDI ARABIA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 94Â Â Â Â Â Â SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 95Â Â Â Â Â Â SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 96Â Â Â Â Â Â SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 97Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE (USD BILLION) 2020-2029
TABLE 98Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE (USD BILLION) 2020-2029
TABLE 99Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
 LIST OF FIGURES
FIGURE 1Â Â Â Â Â MARKET DYNAMICS
FIGURE 2Â Â Â Â Â MARKET SEGMENTATION
FIGURE 3Â Â Â Â Â REPORT TIMELINES: YEARS CONSIDERED
FIGURE 4Â Â Â Â Â DATA TRIANGULATION
FIGURE 5Â Â Â Â Â BOTTOM-UP APPROACH
FIGURE 6Â Â Â Â Â TOP-DOWN APPROACH
FIGURE 7Â Â Â Â Â RESEARCH FLOW
FIGURE 8Â Â Â Â Â GLOBAL LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE, USD BILLION, 2020-2029
FIGURE 9Â Â Â Â Â GLOBAL LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE, USD BILLION, 2020-2029
FIGURE 10Â Â GLOBAL LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE, USD BILLION, 2020-2029
FIGURE 11Â Â Â GLOBAL LUNG CANCER THERAPEUTICS MARKET BY REGION, USD BILLION, 2020-2029
FIGURE 12   PORTER’S FIVE FORCES MODEL
FIGURE 13Â Â Â GLOBAL LUNG CANCER THERAPEUTICS MARKET BY CANCER TYPE, USD BILLION, 2021
FIGURE 14Â Â Â GLOBAL LUNG CANCER THERAPEUTICS MARKET BY MOLECULE TYPE, USD BILLION, 2021
FIGURE 15Â Â Â GLOBAL LUNG CANCER THERAPEUTICS MARKET BY TREATMENT TYPE, USD BILLION, 2021
FIGURE 16Â Â Â GLOBAL LUNG CANCER THERAPEUTICS MARKET BY REGION, USD BILLIONÂ 2021
FIGURE 17Â Â Â MARKET SHARE ANALYSIS
FIGURE 18Â Â Â GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
FIGURE 19Â Â Â PFIZER INC.: COMPANY SNAPSHOT
FIGURE 20Â Â Â SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
FIGURE 21Â Â Â TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
FIGURE 22Â Â Â NOVARTIS AG: COMPANY SNAPSHOT
FIGURE 23Â Â Â ASTRAZENECA: COMPANY SNAPSHOT
FIGURE 24Â Â Â MERCK & CO., INC.: COMPANY SNAPSHOT
FIGURE 25Â Â Â SANOFI: COMPANY SNAPSHOT
FIGURE 26Â Â Â JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
FIGURE 27Â Â Â ALLERGAN: COMPANY SNAPSHOT
FIGURE 28Â Â Â TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
FIGURE 29Â Â Â BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
FAQ
The global lung cancer therapeutics market was valued at 6.83 billion in 2022 and is projected to reach 10.90 billion by 2029, growing at a CAGR of 6.9% from 2022 to 2029
Based on cancer type, molecule type, treatment type, and region the lung cancer therapeutics market reports divisions are broken down.
The global lung cancer therapeutics market registered a CAGR of 6.9% from 2022 to 2029. The industry segment was the highest revenue contributor to the market.
North America had the largest market for lung cancer treatments in 2021, and it is projected that this status will remain during the projection period. The rising incidence of lung cancer and the expanding usage of better diagnosis and lung cancer medications for treatment have led to an increase in the demand for lung cancer treatments in this region.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.